Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| GALT | Galectin Therapeutics | $4.25 | -$1.91 | -31.01% | 58.2K | $397M | $0.73$7.13 |
| PULM | Pulmatrix | $2.83 | -$0.90 | -24.06% | 52.8K | $14M | $2.71$10.40 |
| SAVA | Cassava Sciences | $2.18 | -$0.67 | -23.51% | 1.3M | $138M | $1.15$4.98 |
| ALT | Altimmune | $3.99 | -$1.07 | -21.09% | 6.7M | $527M | $2.90$8.75 |
| NVA | Nova Minerals | $6.72 | -$1.42 | -17.45% | 958.8K | $282M | $1.68$16.28 |
| RKLZ | Tidal Trust II - Defiance Daily Target 2x Short Rklb ETF | $7.05 | -$1.23 | -14.86% | 836.5K | - | $6.75$25.51 |
| BDRX | Biodexa Pharmaceuticals Plc | $3.58 | -$0.57 | -13.73% | 184.4K | $2.6M | $3.55$92.00 |
| FCEL | FuelCell Energy | $8.43 | -$1.21 | -12.55% | 46.6K | $460M | $3.58$13.98 |
| JWEL | Jowell Global | $2.16 | -$0.23 | -9.62% | 7.3K | $5.2M | $1.47$3.26 |
Related Articles
Featured Article
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Adam Spatacco|Aug 9, 2024
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Alex Carchidi|Jul 20, 2024
At least one of the pair has a credible shot at finding a home in the market.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Alex Carchidi|Jul 10, 2024
Both competitors have promising lead programs, and enough cash, too.
Advertisement
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Alex Carchidi|Jun 30, 2024
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Alex Carchidi|Jun 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
Is There Any Hope for Cassava Sciences Stock?
Alex Carchidi|Feb 3, 2024
Battered by controversy, this company will need to show real results to prosper.
1 Big Red Flag to Fear When a Stock Is Down
Alex Carchidi|Oct 31, 2023
Playing the blame game does not make for an effective turnaround strategy.
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
Keith Speights|Mar 22, 2023
It's not the end of the story for this once high-flying biotech stock.
3 Big Reasons to Sell Cassava Sciences Stock Right Now
Alex Carchidi|Feb 1, 2023
It isn't about running out of money, but it's still laden with risk.
My 3 Top Biotech Stock Picks for 2023
George Budwell, PhD|Nov 22, 2022
Biotech stocks are set to shine in 2023.
